HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NCX250

an antiglaucoma agent; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Fabrizi, Francesca: 1 article (02/2012)
2.	Galassi, Fernando: 1 article (02/2012)
3.	Impagnatiello, Francesco: 1 article (02/2012)
4.	Masini, Emanuela: 1 article (02/2012)
5.	Mincione, Francesco: 1 article (02/2012)
6.	Scozzafava, Gabriele: 1 article (02/2012)
7.	Somma, Teresa: 1 article (02/2012)
8.	Supuran, Claudiu T: 1 article (02/2012)

Related Diseases

1.

02/01/2012 - "NCX250 was more effective than DRZ or ISMN on lowering IOP, increasing ocular hemodynamics, decreasing the inflammatory processes and ocular apoptosis in this animal model of glaucoma. "
02/01/2012 - "The clinically used sulfonamide carbonic anhydrase (CA, EC 4.2.1.1) inhibitor dorzolamide (DRZ), a new sulfonamide CA inhibitor also incorporating NO-donating moieties, NCX250, and isosorbide mononitrate (ISMN) (an NO-donating compound with no CA inhibitory properties) were investigated for their intraocular pressure (IOP) lowering effects in rabbits with carbomer-induced glaucoma. "

Related Drugs and Biologics

1.	Sulfonamides
2.	Carbonic Anhydrases (Carbonic Anhydrase)
3.	carbomer
4.	dorzolamide (Trusopt)
5.	isosorbide-5-mononitrate (Ismo)